Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roche Holding AGXSWX:RO +1.29%73 Days Sales Outstanding is 73.42 as of Jun. 2026, which is 13% above its 10-year median of 64.72. GuruFocus rates XSWX:RO with a GF Score™ of 73/100 and a GF Value™ of CHF269.89 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 949 Drug Manufacturers companies, Roche Holding AG ranks better than 50.37% on this metric.
The historical rank and industry rank for Roche Holding AG's Days Sales Outstanding or its related term are showing as below:
XSWX:RO'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.17 Med: 64.72 Max: 71.93
Current: 71.93
During the past 13 years, Roche Holding AG's highest Days Sales Outstanding was 71.93. The lowest was 62.17. And the median was 64.72.
XSWX:RO's Days Sales Outstanding is ranked better than 50.37% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72
vs XSWX:RO: 71.93
Roche Holding AG's Days Sales Outstanding
increased
from Jun. 2025 (68.54) to Jun. 2026 (73.42).
Roche Holding AG (XSWX:RO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Roche Holding AG Days Sales Outstanding Related Terms
Roche Holding AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RO vs LLY, JNJ, ABBV: Days Sales Outstanding Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Days Sales Outstanding falls into.
Roche Holding AG Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:RO) has a Days Sales Outstanding of 73.42 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Roche Holding AG and its competitors. This is 13% above median its historical median of 64.72. Over the past decade, Roche Holding AG's Days Sales Outstanding has ranged from 62.17 to 71.93. According to the industry distribution chart, Roche Holding AG ranks #471 out of 949 companies in the Drug Manufacturers industry, placing it in the top 49.6%.
Is Roche Holding AG's Days Sales Outstanding too high?
Roche Holding AG's current Days Sales Outstanding of 73.42 is 13% above median its 10-year median of 64.72. Over the past 10 years, this metric has ranged from a low of 62.17 to a high of 71.93. The Drug Manufacturers industry median Days Sales Outstanding is 72.00. Roche Holding AG's value of 73.42 is 2% above this industry median. Based on the distribution chart, Roche Holding AG ranks #471 out of 949 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Days Sales Outstanding compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #471 out of 949 companies for Days Sales Outstanding. This puts Roche Holding AG in the upper half of its industry. The industry median Days Sales Outstanding is 72.00. Roche Holding AG's value of 73.42 is 2% above this benchmark. Historically, Roche Holding AG's own Days Sales Outstanding has ranged from 62.17 to 71.93 over the past decade. While the company's 10-year median is 64.72 vs. the industry median of 72.00, Roche Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.00, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current Days Sales Outstanding of 73.42 is 2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current Days Sales Outstanding is 73.42, which is 13% above median its own 10-year median of 64.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF269.89, compared to a current price of CHF360.00 — trading 33.4% above its estimated fair value. The current Days Sales Outstanding is 73.42, which is 13% above median its 10-year median of 64.72 and 2% above the Drug Manufacturers industry median of 72.00. Roche Holding AG's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Days Sales Outstanding is 73.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF360.00 is trading 33.4% above its estimated GF Value™ of CHF269.89.
GuruFocus considers Roche Holding AG to be Significantly Overvalued.
Key valuation signals for XSWX:RO:
Days Sales Outstanding: 73.42 (13% above median its 10-year median of 64.72)
GF Value™: CHF269.89 vs. price of CHF360.00 (33.4% above fair value)
Industry Position: 2% above the Drug Manufacturers median (#471 of 949)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
73GF Score
Get the complete analysis for XSWX:RO
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
